{"id":836580,"date":"2025-04-11T08:04:54","date_gmt":"2025-04-11T12:04:54","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/"},"modified":"2025-04-11T08:04:54","modified_gmt":"2025-04-11T12:04:54","slug":"pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/","title":{"rendered":"Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"<div class=\"mw_release\">\n<p>BRISBANE, Calif., April  11, 2025  (GLOBE NEWSWIRE) &#8212; Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on April 2, 2025 to 18 new employees under Pacira\u2019s Amended and Restated 2014 Inducement Plan (the \u201cInducement Plan\u201d) as a material inducement to each employee\u2019s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People &amp; Compensation Committee of the Board of Directors (the \u201cCommittee\u201d) without stockholder approval.<\/p>\n<p>Nine employees received stock options to purchase an aggregate of 23,100 shares of Pacira common stock and 18 employees received restricted stock units for an aggregate of 43,400 shares of Pacira common stock. The stock options have a 10-year term and a four-year vesting schedule with 25 percent of the underlying shares vesting on the first anniversary of the recipient\u2019s first day of employment and in successive equal quarterly installments over the 36 months thereafter. The stock options have an exercise price of $24.89 per share, the closing trading price of Pacira common stock on the Nasdaq Global Select Market on the date of grant. Each restricted stock unit represents the contingent right to receive one share of Pacira common stock and the restricted stock unit awards vest annually in four equal installments beginning on April 1, 2026.<\/p>\n<p>Vesting of the equity awards is subject to the employee\u2019s continued employment with Pacira. Each equity award is also subject to the terms and conditions of an award agreement.<\/p>\n<p>\n        <strong>About Pacira<\/strong>\n      <\/p>\n<p>Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL<sup>\u00ae<\/sup> (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA<sup>\u00ae<\/sup> (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera<sub>\u00ae<\/sub>\u00ba, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The Company is also advancing the development of PCRX-201, a novel, locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMDgxMiM2ODYyMDYwIzIwMDg5MTE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YjBmMDRjZjgtNDU2Ni00OWI4LWI4NmYtMmM1YzViZGY3M2I2LTEwMjA0ODQtMjAyNS0wNC0xMS1lbg==\/tiny\/Pacira-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Investor Contact:\r\nSusan Mesco, (973) 451-4030\r\nsusan.mesco@pacira.com\r\n\r\nMedia Contact:\r\nSara Marino, (973) 370-5430\r\nsara.marino@pacira.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BRISBANE, Calif., April 11, 2025 (GLOBE NEWSWIRE) &#8212; Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on April 2, 2025 to 18 new employees under Pacira\u2019s Amended and Restated 2014 Inducement Plan (the \u201cInducement Plan\u201d) as a material inducement to each employee\u2019s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People &amp; Compensation Committee of the Board of Directors (the \u201cCommittee\u201d) without stockholder approval. Nine employees received stock options to purchase an aggregate of 23,100 shares of Pacira common stock and 18 employees received restricted stock units for an aggregate of 43,400 shares of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-836580","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BRISBANE, Calif., April 11, 2025 (GLOBE NEWSWIRE) &#8212; Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on April 2, 2025 to 18 new employees under Pacira\u2019s Amended and Restated 2014 Inducement Plan (the \u201cInducement Plan\u201d) as a material inducement to each employee\u2019s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People &amp; Compensation Committee of the Board of Directors (the \u201cCommittee\u201d) without stockholder approval. Nine employees received stock options to purchase an aggregate of 23,100 shares of Pacira common stock and 18 employees received restricted stock units for an aggregate of 43,400 shares of &hellip; Continue reading &quot;Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-11T12:04:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMDgxMiM2ODYyMDYwIzIwMDg5MTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2025-04-11T12:04:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\\\/\"},\"wordCount\":395,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMDgxMiM2ODYyMDYwIzIwMDg5MTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\\\/\",\"name\":\"Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMDgxMiM2ODYyMDYwIzIwMDg5MTE=\",\"datePublished\":\"2025-04-11T12:04:54+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMDgxMiM2ODYyMDYwIzIwMDg5MTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMDgxMiM2ODYyMDYwIzIwMDg5MTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/","og_locale":"en_US","og_type":"article","og_title":"Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"BRISBANE, Calif., April 11, 2025 (GLOBE NEWSWIRE) &#8212; Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on April 2, 2025 to 18 new employees under Pacira\u2019s Amended and Restated 2014 Inducement Plan (the \u201cInducement Plan\u201d) as a material inducement to each employee\u2019s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People &amp; Compensation Committee of the Board of Directors (the \u201cCommittee\u201d) without stockholder approval. Nine employees received stock options to purchase an aggregate of 23,100 shares of Pacira common stock and 18 employees received restricted stock units for an aggregate of 43,400 shares of &hellip; Continue reading \"Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-11T12:04:54+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMDgxMiM2ODYyMDYwIzIwMDg5MTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2025-04-11T12:04:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/"},"wordCount":395,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMDgxMiM2ODYyMDYwIzIwMDg5MTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/","name":"Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMDgxMiM2ODYyMDYwIzIwMDg5MTE=","datePublished":"2025-04-11T12:04:54+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMDgxMiM2ODYyMDYwIzIwMDg5MTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMDgxMiM2ODYyMDYwIzIwMDg5MTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/836580","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=836580"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/836580\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=836580"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=836580"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=836580"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}